Market Place
Sourcing Support
Zydus Lifesciences gets USFDA nod to market Scopolamine transdermal system
30 Aug 2024 //
ECONOMICTIMES
Zydus`s Generics Scopolamine Receives Approval in US
29 Aug 2024 //
FDA
Defender gets CRL from FDA on motion sickness nasal gel
31 Jan 2024 //
FIERCE PHARMA
Defender Receives CRL from the USFDA for its Intranasal Scopolamine
30 Jan 2024 //
GLOBENEWSWIRE
FDA Accepts Defender™ New Drug Application for Intranasal Scopolamine Gel
26 Sep 2023 //
GLOBENEWSWIRE
Defender Announces Submission of NDA to FDA with Intranasal Scopolamine
26 Jul 2023 //
GLOBENEWSWIRE
Defender Reports Positive Results from Pivotal PIII Trial of Scopolamine
05 Jun 2023 //
GLOBENEWSWIRE
Enforcement Report - Week of February 1, 2023
01 Feb 2023 //
FDA
Actavis Lab`s Generic Scopolamine Receives Approval in the U.S.
10 Jan 2022 //
FDA
Riconpharma`s Generic Triazolam Receives Approval in US
28 Nov 2020 //
FDA
Scopolamine Base, Hydrobromide & Methylbromide - niche Phyto API’s from Transo-Pharm
27 Aug 2019 //
PRESS RELEASE
Mylan Technologies` Generic Scopolamine Receives Approval in US
19 Jun 2019 //
FDA
Enforcement Report - Week of May 23, 2018
23 May 2018 //
FDA
Perrigo Announces The Launch Of The AB Rated Generic Transderm Scop® 1.5 mg
31 Jul 2017 //
PR NEWSWIRE
WHO hopeful Assad Government will allow surgical supplies into Moadamiyeh
03 Mar 2016 //
IN-PHARMATECHNOLOGIST
Anvisa Suspends Distribution of Ceara Ltds’ Injectable Products on Failing the Look Test
08 Apr 2015 //
ANVISA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.